BioAtla (BCAB) Share-based Compensation (2020 - 2026)
BioAtla (BCAB) posted quarterly Share-based Compensation of $1.7 million for Q1 2026, up 3.34% year-over-year from $1.6 million in Q1 2025, and up 51.79% quarter-over-quarter from $1.1 million in Q4 2025.
BioAtla (BCAB) Share-based Compensation (2020 - 2026) Analysis & Trends
BioAtla's Share-based Compensation history runs 7 years deep, the most recent figure standing at $1.7 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 3.34% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (down 79.43% YoY), while the FY2025 annual figure was $5.4 million, down 39.09% from the prior year.
- Share-based Compensation for Q1 2026 stood at $1.7 million, up from $1.1 million in the prior quarter.
- The five-year high for Share-based Compensation was $3.8 million in Q2 2022, with the low at $1.1 million in Q4 2025.
- The 5-year median for Share-based Compensation is $2.7 million (2023), against an average of $2.7 million.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation plunged 68.76% in 2022, then surged 64.08% in 2025.
- BioAtla's Share-based Compensation stood at $3.5 million in 2022, then fell by 21.79% to $2.7 million in 2023, then decreased by 29.47% to $1.9 million in 2024, then plunged by 42.0% to $1.1 million in 2025, then soared by 51.79% to $1.7 million in 2026.
- Business Quant data shows BCAB's Share-based Compensation at $1.7 million in Q1 2026, $1.1 million in Q4 2025, and $3.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | BioAtla | 5.28 Mn | 5.28 Mn | - | 619,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 619,000.00 |
| Jun 30, 2026 | 619,000.00 |
| Mar 31, 2026 | 1.70 Mn |
| Mar 31, 2026 | 1.70 Mn |
| Dec 31, 2025 | 1.12 Mn |
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | 3.60 Mn |
| Sep 30, 2025 | 3.60 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Mar 31, 2025 | 1.65 Mn |
| Mar 31, 2025 | 1.65 Mn |
| Dec 31, 2024 | 1.93 Mn |
| Dec 31, 2024 | 1.93 Mn |
| Sep 30, 2024 | 2.19 Mn |
| Sep 30, 2024 | 2.19 Mn |
| Jun 30, 2024 | 2.50 Mn |
| Jun 30, 2024 | 2.50 Mn |
| Mar 31, 2024 | 2.30 Mn |
| Mar 31, 2024 | 2.30 Mn |